Upconverting and NIR emitting rare earth based nanostructures for NIR-bioimaging.

In recent years, significant progress was achieved in the field of nanomedicine and bioimaging, but the development of new biomarkers for reliable detection of diseases at an early stage, molecular imaging, targeting and therapy remains crucial. The disadvantages of commonly used organic dyes include photobleaching, autofluorescence, phototoxicity and scattering when UV (ultraviolet) or visible light is used for excitation. The limited penetration depth of the excitation light and the visible emission into and from the biological tissue is a further drawback with regard to in vivo bioimaging. Lanthanide containing inorganic nanostructures emitting in the near-infrared (NIR) range under NIR excitation may overcome those problems. Due to the outstanding optical and magnetic properties of lanthanide ions (Ln(3+)), nanoscopic host materials doped with Ln(3+), e.g. Y2O3:Er(3+),Yb(3+), are promising candidates for NIR-NIR bioimaging. Ln(3+)-doped gadolinium-based inorganic nanostructures, such as Gd2O3:Er(3+),Yb(3+), have a high potential as opto-magnetic markers allowing the combination of time-resolved optical imaging and magnetic resonance imaging (MRI) of high spatial resolution. Recent progress in our research on over-1000 nm NIR fluorescent nanoprobes for in vivo NIR-NIR bioimaging will be discussed in this review.

Cytotoxic aspects of gadolinium oxide nanostructures for up-conversion and NIR bioimaging.

Bioimaging is an important diagnostic tool in the investigation and visualization of biological phenomena in cells and in medicine. In this context, up-converting Gd(2)O(3):Er(3+),Yb(3+) nanostructures (nanoparticles, nanorods) have been synthesized by precipitation methods and hydrothermal synthesis. Independent of size and morphology, Gd(2)O(3):Er(3+),Yb(3+) powders show up-conversion (550 nm, 670 nm) and near-infrared emission (1.5 µm) upon 980 nm excitation, which makes these structures interesting for application as biomarkers. With regard to their potential application in bioimaging, cytotoxicity is an important aspect and is strongly affected by the physico-chemical properties of the investigated nanostructures. Therefore, the cytotoxic effect of bare and poly(ethylene glycol)-b-poly(acrylic acid) block co-polymer-modified nanostructures on non-phagocytic and phagocytic cells (B-cell hybridoma cells and macrophages) was investigated. The observed cytotoxic behavior in the case of macrophages incubated with bare nanostructures was assigned to the poor chemical durability of gadolinium oxide, but could be overcome by surface modification.

In vitro and in vivo investigations of upconversion and NIR emitting Gd2O3:Er³âº,Yb³âº nanostructures for biomedical applications.

The use of an "over 1000-nm near-infrared (NIR) in vivo fluorescence bioimaging" system based on lanthanide containing inorganic nanostructures emitting in the visible and NIR range under 980-nm excitation is proposed. It may overcome problems of currently used biomarkers including color fading, phototoxicity and scattering. Gd(2)O(3):Er(3+),Yb(3+) nanoparticles and nanorods showing upconversion and NIR emission are synthesized and their cytotoxic behavior is investigated by incubation with B-cell hybridomas and macrophages. Surface modification with PEG-b-PAAc provides the necessary chemical durability reducing the release of toxic Gd(3+) ions. NIR fluorescence microscopy is used to investigate the suitability of the nanostructures as NIR-NIR biomarkers. The in vitro uptake of bare and modified nanostructures by macrophages is investigated by confocal laser scanning microscopy. In vivo investigations revealed nanostructures in liver, lung, kidneys and spleen a few hours after injection into mice, while most of the nanostructures have been removed from the body after 24 h.

RETRACTED: Photocatalytic activity of Bi-doped TiO(2) in the degradation of monocrotophos in aqueous solution.

This article has been retracted consistent with Elsevier Policy on Article Withdrawal. Please see . The Publisher apologizes for any inconvenience this may cause.